Shots:

• TXMD to receive ~$153.1M incl. $140.0M up front for license grant & sale of assets & ~$13.1M in net working capital, ~$42.6M in minimum royalty ($3.0M per yr. for 12yrs.). The transaction is expected to close at the end of 2022 & allow TXMD to recapitalize & transform into a pharmaceutical royalty company
• TXMD receives ~$30.0M in milestones incl. $5.0M if net revenue of all products in the US reaches $100.0M; $10.0M if revenue reaches $200.0M & $15.0M upon the reach of $300.0M & royalties of 8.0% on $80.0M & 7.5% on above $80.0M
• Mayne to get an exclusive US commercialization right for TXMD’s products incl. Imvexxy, Bijuva, prescription prenatal vitamin products (under the BocaGreenMD and vitaMedMD brands) & Annovera in the US along with certain assets for products, incl. inventory

Ref: Businesswire | Image: Mayne Pharma